암 화학요법 관련 오심 및 구토 치료제 시장 : 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별

Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market is estimated to be valued at USD 3,431.0 Mn in 2025 and is expected to reach USD 5,057.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

Treatment for cancer patients must prioritize preventing and controlling nausea and vomiting (N&V). One of the most prevalent and upsetting acute adverse effects of chemotherapy-induced nausea and vomiting (N&V) is cancer treatment. It can significantly lower a patient's quality of life and happens in up to 80% of patients. The perceptual feeling of nausea is an unpleasant, wave-like sensation in the epigastrium and/or back of the throat that may lead to vomiting (emesis). Emesis, the violent evacuation of stomach, duodenal, or jejunal contents through the oral canal, is referred to as vomiting. Retching, also known as dry heaves, involves the stomach and esophageal motions of vomiting without the evacuation of vomitus. Understanding the neurophysiological systems that regulate nausea and vomiting (N&V) has advanced. The central nervous system regulates or mediates both, but through different ways. The autonomic nervous system is the mechanism that causes nausea.

A complicated response that includes the convergence of afferent input is stimulated during vomiting. Neurotransmitters in the chemoreceptor trigger zone, the vomiting center (said to be situated in the nucleus tractus solitarius), and enterochromaffin cells in the gastrointestinal tract emit efferent impulses. These neurotransmitters include serotonin, substance P, and dopamine. These signals are sent to the respiratory center, salivation center, and abdominal muscles. The relative importance of these several routes, which result in N&V symptoms, is complicated. It is proposed to explain agents' varying emetogenicity (intrinsic emetogenicity and mitigating variables [i.e., dose, administration method, and exposure length]) and emetogenic profile (i.e., time to onset, intensity, and duration of symptoms).

Market Dynamics

Chemotherapy-induced nausea and vomiting (CINV) drugs are given to patients who undergo chemotherapy treatment to prevent nausea and vomiting. An increase in the number of patients undergoing chemotherapy is expected to drive the market growth over the forecast period. For instance, according to the data provided by the Centers for Disease Control and Prevention, in November 2022, more than 1 million cancer patients receive chemotherapy or radiation in an outpatient oncology clinic in the U.S. each year.

Key features of the study:

• This report provides an in-depth analysis of the global cancer chemotherapy associated nausea and vomiting therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cancer chemotherapy associated nausea and vomiting therapeutics market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eisai Co., Ltd., Pharmanovia, Novartis AG, Merck & Co., Inc., Helsinn Healthcare SA, Dr. Reddy's Laboratories Ltd., Validus Pharmaceuticals LLC, LGM Pharma, Astellas Pharma Inc., AdvaCare Pharma, Norgine, PV Pharma, Fresenius Kabi, Lupin, Hetero Healthcare Limited., Sino Biopharmaceutical Limited, Glenmark Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, OPKO Health, Inc., Weefsel Pharma, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Starton Therapeutics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cancer chemotherapy associated nausea and vomiting therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer chemotherapy associated nausea and vomiting therapeutics market

Detailed Segmentation:

• Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type:
  • Acute CINV
  • Delayed CINV
  • Anticipatory nausea and emesis
  • Breakthrough CINV/Refractory CINV
• Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Drug Class:
  • Dopamine Receptor Antagonists
  • Metoclopramide
  • Chlorpromazine
  • Prochlorperazine
  • Haloperidol
  • Droperidol
  • Others
  • Serotonin (5-HT3) receptor Antagonists
  • Ondansetron
  • Granisetron
  • Palonosetron
  • Dolasetron
  • Others
  • Substance P/NK-1 Antagonists
  • Aprepitant
  • Fosaprepitant
  • Netupitant
  • Others
  • Corticosteroids
  • Dexamethasone
  • Methylprednisolone
  • Others
• Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Route of Administration:
  • Oral
  • Parenteral
  • Transdermal Patch
• Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Region:
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Eisai Co., Ltd.
  • Pharmanovia
  • Novartis AG
  • Merck & Co., Inc.
  • Helsinn Healthcare SA
  • Reddy's Laboratories Ltd.
  • Validus Pharmaceuticals LLC
  • LGM Pharma
  • Astellas Pharma Inc.
  • AdvaCare Pharma
  • Norgine
  • PV Pharma
  • Fresenius Kabi
  • Lupin
  • Hetero Healthcare Limited.
  • Sino Biopharmaceutical Limited
  • Glenmark Pharmaceuticals Ltd.
  • Otsuka Pharmaceutical Co., Ltd
  • OPKO Health, Inc.
  • Weefsel Pharma
  • Pfizer Inc.
  • Rosemont Pharmaceuticals Ltd.
  • Starton Therapeutics.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Key Developments
• PEST Analysis
• PORTER's Analysis
• Regulatory Scenario
• Merger, Collaboration and Acquisition Scenario
• Product Launches/Approvals
• Epidemiology

4. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market- COVID-19 Impact Analysis

• Economic Impact
• Overall Impact on Healthcare Sector
• COVID-19 Epidemiology

5. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Acute CINV
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Delayed CINV
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Anticipatory nausea and emesis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Breakthrough CINV/Refractory CINV
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

6. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Drug Class, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Dopamine Receptor Antagonists
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Metoclopramide
• Chlorpromazine
• Prochlorperazine
• Haloperidol
• Droperidol
• Others
• Serotonin (5-HT3) receptor Antagonists
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Ondansetron
• Granisetron
• Palonosetron
• Dolasetron
• Others
• Substance P/NK-1 Antagonists
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Aprepitant
• Fosaprepitant
• Netupitant
• Others
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Dexamethasone
• Methylprednisolone
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

7. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Route of Administration, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Transdermal Patch
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

8. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Distribution Channel, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

9. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Region, 2020 - 2032, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Eisai Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pharmanovia
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlight
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlight
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Helsinn Healthcare SA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Reddy's Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Validus Pharmaceuticals LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• LGM Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Astellas Pharma Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AdvaCare Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Norgine
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• PV Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Fresenius Kabi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lupin
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Hetero Healthcare Limited.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sino Biopharmaceutical Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Glenmark Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Otsuka Pharmaceutical Co., Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• OPKO Health, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Weefsel Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Rosemont Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Starton Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

11. Section

• Research Methodology
• About Us